Due to the lack of secure, efficient, and patient-friendly therapies for neurodegenerative disorders, there is a rising demand for innovative approaches. Despite the limited number of nanocarriers approved for human use, they have demonstrated significant potential in preclinical and, in some instances, clinical trials. In alignment with this objective, the chapters of the book are structured to offer a comprehensive overview of recent advancements in medication and dosage form development, specifically emphasizing the nanoparticulate system for targeting the brain. This book aims to furnish readers with a thorough understanding of the clinical application of nanocarrier systems for treating neurodegenerative disorders, encompassing the latest developments, challenges, safety concerns, toxicity issues, regulatory considerations, prospects, and limitations. Individuals in academia, the scientific community, business, and education seeking a more effective approach to target the brain will find valuable insights in this resource.
Key Features
Provides a comparative perspective of various nanocarrier systems, therefore facilitating the researcher's selection of appropriate nanoparticulate carriers Highlights the related restrictions of brain delivery and current available medicines Includes information on the advantages and disadvantages of various biomaterials utilized in the development of nanocarriers for brain targeting Emphasizes distinct facets of surface functionalization according to the brain area of interest Presents the current advances, preclinical and clinical development, and the future potential of multiple brain-targeting technologies
Edited by:
Wael Mohamed
Imprint: CRC Press
Country of Publication: United Kingdom
Dimensions:
Height: 280mm,
Width: 210mm,
Weight: 834g
ISBN: 9781032467955
ISBN 10: 1032467959
Pages: 348
Publication Date: 30 September 2024
Audience:
College/higher education
,
Professional and scholarly
,
Primary
,
Undergraduate
Format: Hardback
Publisher's Status: Active
SECTION-I: NANOMEDICINE IN NEURODEGENERATIVE DISORDERS Ch1 - Fundamentals of Brain–Barrier Anatomy and Global Functions Yasser Mecheri, Soundous Malak Behloul Ch2 - Blood Brain Barrier in Neurodegenrative Disorders Adejoke Elizabeth Memudu, Michael Oluwatosin Gabriel Ch3 - Neurodegenerative Disorders, available therapies, and their limitations Mohamed Zaki , Eman E. Mohamed , Osama M. Ahmed Ch4 - Challenges in brain targeting and mechanism of drug transfer across BBB Ahmad Kodous, Priya Ramanathan, Arunagiri Kuha Deva Magendhra Rao, Gamal Abdel Nasser Atia Ch5 - Introduction to Nanomedicine, Nanotechnology and Nanopharmaceuticals Abdullah M. M. Elbadry, Hend H. Mohamed Ch6 - Regulations and Ethics of Nanomedicine and Public acceptance Nada Abdel-Monaem Ch7 - Safety of Nanoparticles in Medicine Mona Mohammed Abd elHakeem khalifa Ch8 - Enhancing Brain Drug Delivery with Lipid Nanocarriers for Bioactive Compounds Shivakumar M Methri, Sivakumar Manickam, V. Ravichandiran, Subramanian Natesan Ch9 - Blood brain Barrier disruption and Nanomedicine in Neurodegenerative disorders Adejoke Elizabeth Memudu, Michael Oluwatosin Gabriel, Grace Temitope Akingbade, Happiness Ochi Inyang, Omamuyovwi Meashack Ijomone Ch10 - Worldwide Development and Commercialization of Nanomedicine Hadeer N. Atalah, Esraa M. Qansuwa SECTION-II: NANOPARTICLES AND NEURODEGENERATIVE DISORDERS Ch11 - Introduction to nanoparticles as a potential carrier for brain targeting in Neurodegenerative Disorders Adejoke Elizabeth Memudu, Michael Oluwatosin Gabriel, Victor Ebube Anadu, Olayemi Kafilat Ijomone, Omamuyovwi Meashack Ijomone Ch12 - Application of polymeric nanoparticles in brain targeting Moshera Samy Ch13 - Lipid-based Nanocarriers for Brain Delivery of Bio-actives in the Treatment of Neurodegenerative Disorders Khaled M. Kotb, Mohamed N. Sharafeldin, Hamsa Hassan, Achouak BOUTALBI, Ahmed Yahya, Haseen Fatima Niazi, Nouran A. Taha, Islam Omar, Amgad E. Salem Ch14 - Autophagy and extracellular nanovesicles communication and their therapeutic application in neurodegenerative diseases. Mohamed Abdelkader, Noha AboQuella Ch15 - Mesoporous silica nanoparticles as promising carriers for brain delivery Sudarshan Naidu Chilamakuri, Sivakumar Manickam, Rajukumar Malayandi Ravichandiran Velayutham, Subramanian Natesan Ch16 - Potential of dendrimers as a nanocarrier for brain drug delivery Arab Iram Saba Gaus Mohammed, Victor Hmingthansanga, Sivakumar Manickam, V. Ravichandiran, Subramanian Natesan Ch17 - Surface active ligands for brain targeting Mariam Zewail, Heba Abd-El-Azim Ch18 - Nanocarriers for brain delivery: Safety, Stability concerns, and regulatory aspects Asmaa Ashraf, Mohamed Dahab, Rahma Soliman Ch19 - Advancements of nanocarriers for brain targeting and limitations in clinical translation Nermeen Z. Abuelezz, Fayza Eid Nasr, María-Salud García-Ayllón, Javier Sáez-Valero Ch20 - Toward Applicability of Exosomal-ncRNA Precision vs Nanoparticles to the Brain Nadia M. Hamdy, Emad B. Basalious, Mona G. El-Sisi, Rana A. Youness, Ahmed S. Sultan Ch21 - Current advancements of nanocarriers for neurodegenerative disorders linked to toxoplasmosis Mohamed Y. Zaky, Nahed S. Lamloum Ch22 - Toward Nano-drugs Precision for Neurodegenerative disease(s) or Glioma Nadia M. Hamdy, Emad B. Basalious, Al-Aliaa Sallam, Fatma H. Shaker, Sujay Paul, Shih-Min Hsia, Mai M. Anwar
Dr. Wael Mohamed Yousef Mohamed, a Physician Neuroscientist, earned his PhD from PSU in the USA and currently holds the position of Associate Professor at IIUM Medical School in Malaysia. With an extensive background, Dr. Mohamed has been invited to deliver over 150 lectures both domestically and internationally. His contributions to Neuroscience/Psychiatry are notable, with the publication of more than 100 peer-reviewed papers, boasting an h-index of 20. Furthermore, Dr. Mohamed serves as an editor for Frontiers in Neurology and PLOS-ONE Journals, where he has contributed to various journal special issues on brain disorders. In the realm of book editing, he is actively involved with Springer, CRC, and Cambridge in the field of neuroscience. His research endeavors have attracted numerous grants from esteemed national and international organizations, including IBRO, ISN, MJF, STDF, FRGS, and INDO-ASEAN, amounting to a total research funding of half a million US$. Notably, he is the founder and chair of the AfrAbia-PD-Genomic Consortium.
